Targeting up-regulated cIAP2 in SOX10-deficient drug tolerant melanoma

• Published in: Molecular cancer therapeutics Vol. 22; no. 9; pp. 1087 - 1099
• Main Authors: Glasheen, McKenna Q., Caksa, Signe, Young, Amelia G., Wilski, Nicole A., Ott, Connor A., Chervoneva, Inna, Flaherty, Keith T., Herlyn, Meenhard, Xu, Xiaowei, Aplin, Andrew E., Capparelli, Claudia
• Format: Journal Article
• Language: English
• Published: 05-09-2023
• ISSN: 1535-7163; 1538-8514
• DOI: 10.1158/1535-7163.MCT-23-0025

Drug tolerance and minimal residual disease (MRD) are likely to prelude acquired resistance to targeted therapy. Mechanisms that allow persister cells to survive in the presence of targeted therapy are being characterized but selective vulnerabilities for these subpopulations remain uncertain. We identified cellular inhibitor of apoptosis protein 2 (cIAP2) as being highly expressed in SOX10-deficient drug tolerant persister (DTP) melanoma cells. Here, we show that cIAP2 is sufficient to induce tolerance to MEK inhibitors, likely by decreasing the levels of cell death. Mechanistically, cIAP2 is upregulated at the transcript level in SOX10-deficient cells and the AP-1 complex protein, JUND, is required for its expression. Using a patient-derived xenograft model, we demonstrate that treatment with the cIAP1/2 inhibitor, birinapant, during the MRD phase delays the onset of resistance to BRAF inhibitor and MEK inhibitor combination therapy. Together, our data suggest that cIAP2 upregulation in SOX10-deficient subpopulations of melanoma cells induces drug tolerance to MAPK targeting agents and provides a rationale to test a novel therapeutical approach to target MRD.